Powered by the Consumer Technology Association (CTA)®

LAST CHANCE: Register before December 5 to save $200 on your CES 2025 registration!

Skip to content
2025 Honoree Award

MOGLU: Noninvasive Continuous Glucose Monitoring Device

Apollon
  • 2025 Honoree in Digital Health

MOGLU is a noninvasive continuous glucose monitoring (CGM) device designed to revolutionize diabetes care. Using innovative Raman spectroscopy technology, it detects glucose-reactive signals on the skin, reducing costs and enhancing convenience. We are the only team worldwide to directly observe in vivo Raman signals for glucose. Since 2023, we've collaborated with Professor Peter So's team at MIT's Biological Engineering department on clinical trials. We plan to conduct larger trials at the Joslin Diabetes Center later this year and aim for FDA approval in 2025. Our data so far indicates that MOGLU could potentially become the first FDA-approved noninvasive CGM.

Learn More About Digital Health at CES

Explore the latest advancements in AI, IoT, telehealth, and digital health solutions. These groundbreaking technologies are reshaping healthcare delivery, improving patient outcomes, and enhancing operational efficiency.

Alt text: A Man with short dark hair in a white lab coat stands confidently against a vibrant, abstract background with flowing shapes in blue, purple, green and white.

See More Innovation Awards